Legend Biotech Corporation (LEGN) Stock Price & How to Invest
Last updated November 2026
Short answer
LEGN is Legend Biotech, a commercial-stage cell-therapy company whose value rests almost entirely on CARVYKTI, the BCMA-directed CAR-T for multiple myeloma it co-develops and shares profits on with Johnson & Johnson. Investing in it means betting that CARVYKTI keeps scaling toward blockbuster status and that Legend converts its first profitable quarters into durable profit. As of November 20, 2026 the ADRs closed near $15.42, down about 28% year to date and about 44% over one year, for a market cap around $3.0 billion, after an 18% one-day drop on November 10 when third-quarter results showed US CARVYKTI growth slowing to 19%.
LEGN stock price
As of 2026-11-20, Legend Biotech Corporation (LEGN) last closed at $15.25, down 45.9% over the past year. Over the past 52 weeks it has traded between $15.25 and $36.28.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Legend Biotech Corporation's investor relations page. Walnut is informational, not investment advice.
LEGN key stats
At $15.25 on November 20, 2026, Legend Biotech Corporation (LEGN) has a market cap of $3.0B.
- Market cap
- $3.0B
- P/E (forward)
- 28.9
- Price to book
- 2.3
- Beta
- 0.55
Market cap, P/E and yield are measured at the $15.25 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Legend Biotech Corporation (LEGN)?
The last two weeks for Legend Biotech Corporation, as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- LEGN closed at $15.25 on November 20, 2026, down 12.9% over the past five trading days (from $17.50).
- On November 10, 2026, Legend Biotech Corporation filed a current report (6-K) with the SEC. Read the 6-K on sec.gov
- On November 16, 2026, Evercore ISI Group started coverage at In-Line, target $20.00.
- On November 11, 2026, Oppenheimer lowered its target to $25.00 from $40.00 (Perform).
- On November 11, 2026, Morgan Stanley lowered its target to $43.00 from $49.00 (Overweight).
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
What does Legend Biotech Corporation (LEGN) do?
Legend Biotech is a global cell-therapy company best known for CARVYKTI (ciltacabtagene autoleucel, or cilta-cel), a one-time BCMA-directed CAR-T treatment for relapsed or refractory multiple myeloma. It develops and commercializes CARVYKTI in a 50/50 profit-and-cost-sharing collaboration with Johnson & Johnson, so Legend's reported revenue shows up largely as collaboration and license income rather than direct product sales. The company also runs an earlier-stage pipeline of other cell therapies and solid-tumor programs, but CARVYKTI drives essentially all of the current commercial narrative. Ingrid Zhang became chief executive effective September 15, 2026.
The investment picture is a scaling-into-profitability story. CARVYKTI reached roughly $1.9 billion in global net trade sales in 2025 and grew about 62 percent year over year in the first quarter of 2026, helped by earlier-line use and expanded manufacturing; it is now available at 373 sites in 20 markets. Legend has moved from losses to GAAP profit while holding a sizable cash cushion, but it remains dependent on one franchise, on J&J as its commercial partner, and on a competitive multiple-myeloma market. The stock trades as a growth biotech, so results and the durability of profit matter a great deal.
Q2 2026 delivered the profit milestone: total revenue of about $387.5 million (up about 52% year over year) and net income of about $33.2 million. Q3 2026, reported November 10, followed with CARVYKTI net trade sales of about $710 million, up 36% year over year, of which Legend's half was about $355 million. Total revenue was about $359.5 million, up 32% but below Q2 and in line with the roughly $360 million consensus, and net income was about $51.7 million (adjusted EPS of $0.14 per ordinary share, about $0.28 on Yahoo Finance's per-ADR basis, versus a $0.01 consensus). The detail that moved the stock was geography: US sales grew 19%, down from 32% the quarter before, while ex-US sales grew 86%, and the CFO said earlier-line US share gains had been slower than expected. The shares fell about 18% that day, their worst session on record. Trailing revenue reached about $1.36 billion, trailing net income is roughly breakeven, and the company held about $853 million of cash and time deposits against about $167 million of debt at September 30, 2026. Earlier highlights included five-year CARVYKTI data in September showing half of relapsed or refractory myeloma patients alive and progression-free after a single infusion, the October 15 FDA clearance of the IND for LB2501, an investigational CD19/CD20 in vivo CAR-T, and updated NCCN guidelines that favor BCMA CAR-T over T-cell engagers when both are viable. RBC cut its target to $50 from $56 after the report while keeping an outperform rating.
What's driving Legend Biotech Corporation (LEGN)?
1. CARVYKTI commercial ramp
CARVYKTI net trade sales reached about $1.9 billion in 2025, rose roughly 62 percent year over year in Q1 2026 and about 36 percent in Q3 2026 to around $710 million, with ex-US sales growing far faster than US sales off a smaller base (86% versus 19% in Q3). The franchise is now available in 20 markets and 373 sites, and management has pointed to expanding manufacturing capacity as the key throughput lever. Continued volume growth is the single largest driver of the story, and the Q3 slowdown in the US is now the number the market is watching most closely. RBC said after the report that it sees CARVYKTI positioned to sustain growth into 2027.
2. Move to earlier lines of therapy
Approvals expanding CARVYKTI into earlier treatment lines widen the eligible patient pool well beyond heavily pretreated patients. Earlier use, if supported by durable outcomes data, is what supports the multibillion-dollar sales trajectory analysts model. Adoption depends on physician comfort with CAR-T logistics versus off-the-shelf alternatives, and the CFO said in November 2026 that US share gains in earlier lines had come slower than expected. Legend estimated earlier in 2026 that about 41% of current US CARVYKTI use was already in second- and third-line patients, while the rest sat in the fourth-line-plus setting where Gilead's anito-cel would compete first if approved. Five-year data released in September 2026, with half of patients alive and progression-free, and NCCN guidance to refer patients to a T-cell therapy center at first relapse strengthen the durability argument.
3. Path to profitability
Legend narrowed its net loss substantially in Q1 2026 (adjusted net loss of about $10.5 million) after a full-year 2025 adjusted net loss of roughly $33 million. The J&J profit split means margin leverage builds as CARVYKTI scales. Legend then reported GAAP net income of about $33.2 million in Q2 2026 and about $51.7 million in Q3, and its forward-looking statements still point to profitability for full-year 2026. Sustaining that profit remains the central proof point: trailing net income is now roughly breakeven, operating cash flow over the trailing twelve months was still negative (about -$154 million), consensus sees about $0.12 of EPS for 2026, and analysts expect about $0.54 per share in 2027.
4. Pipeline optionality
Beyond CARVYKTI, Legend is advancing earlier-stage cell therapies including next-generation and solid-tumor programs. These are largely unproven and years from meaningful revenue, so they are long-dated optionality rather than a current earnings contributor. Any clinical readout that de-risks a second franchise would matter given the current single-product concentration. The October 2026 FDA clearance of the IND for LB2501, a CD19/CD20 in vivo CAR-T designed to be generated inside the patient's body rather than manufactured from extracted cells, adds a new clinical-stage program, with a US Phase I/II trial planned.
What are the risks to Legend Biotech Corporation (LEGN)?
Legend's value is heavily concentrated in one product, CARVYKTI, and in one partner, Johnson & Johnson, which shares profits and controls much of the commercial engine. The multiple-myeloma market is increasingly crowded, with competing CAR-T therapies like Bristol Myers Squibb's Abecma and off-the-shelf BCMA bispecific antibodies such as J&J's Tecvayli and Pfizer's Elrexfio that avoid CAR-T's manufacturing and logistics burden. Gilead's anito-cel, another BCMA CAR-T, has an FDA decision date of December 23, 2026, and Legend has estimated that about 59% of the US CARVYKTI market sits in the fourth-line-plus segment where anito-cel is expected to be labeled; UBS also flagged J&J's Tec-Dara as a threat in earlier lines. US growth already slowed to 19% in Q3 2026 from 32% the quarter before, and Q4 consensus sat at the high end of management's scenarios, so further deceleration is a live risk. CAR-T therapies also carry serious safety considerations and manufacturing and capacity constraints that can cap growth. The company only reached quarterly GAAP profit in Q2 2026 and its trailing earnings are roughly breakeven, so any sales miss, pricing pressure, or safety signal can move the stock sharply, as the 18% drop on November 10 showed. A new chief executive took over in September 2026. As a China-founded, US-listed ADR, it also carries geopolitical, supply-chain, and regulatory exposure that pure-play US biotechs do not.
What is the Legend Biotech Corporation (LEGN) forecast?
14 analysts publish price targets on LEGN, averaging $40.93 as of November 2026, or +168.4% against the $15.25 share price on November 20, 2026. The published targets run from $20.00 to $65.00, a wide spread, and the ratings split 8 buy, 6 hold, 0 sell. Over the last six months there has been 1 raise and 8 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full LEGN forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is LEGN a buy or a sell?
We give no verdict on Legend Biotech Corporation. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. CARVYKTI commercial ramp. CARVYKTI net trade sales reached about $1.9 billion in 2025, rose roughly 62 percent year over year in Q1 2026 and about 36 percent in Q3 2026 to around $710 million, with ex-US sales growing far faster than US sales off a smaller base (86% versus 19% in Q3). The most optimistic published target, $65.00, assumes this works close to its best case.
The case against. Legend's value is heavily concentrated in one product, CARVYKTI, and in one partner, Johnson & Johnson, which shares profits and controls much of the commercial engine. The most pessimistic target, $20.00, is roughly what LEGN is worth if this bites instead.
Read the full bull and bear case on LEGN, including what would have to change to break either one. Walnut is not an investment adviser.
Has Legend Biotech Corporation (LEGN) split its stock?
No. Legend Biotech Corporation (LEGN) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.
How is Legend Biotech Corporation (LEGN) valued?
Market cap, P/E and dividend yield at today's price are in the LEGN key stats above. The business figures below come from Legend Biotech Corporation's reported results as of November 2026 and change when it next reports.
- Revenue (TTM, collaboration/license): ~$1.36B
- Q3 2026 total revenue: ~$359.5M (up ~32% YoY)
- Q3 2026 CARVYKTI net trade sales: ~$710M (up ~36% YoY; US +19%, ex-US +86%)
- Q3 2026 net income: ~$51.7M
- Net income (TTM): ~breakeven
- Cash / debt (Sept 30, 2026): ~$853M / ~$167M
As of November 2026: LEGN's revenue is recognized mainly as collaboration and license income under the J&J profit split, distinct from CARVYKTI's roughly $710 million of Q3 2026 global net trade sales. At about $15.42 on November 20, 2026 the ADRs trade near 2.2 times trailing sales and about 29 times forward EPS estimates, close to their 52-week low of $15.36, because slowing US growth and competition from anito-cel and bispecifics now weigh on how long the ramp lasts. The 14 covering analysts carry a consensus buy rating and a mean target near $41, though RBC trimmed its target to $50 after the Q3 report and UBS had already cut to $24.
Who competes with Legend Biotech Corporation (LEGN)?
Competing CAR-T therapies
Bristol Myers Squibb and 2seventy bio's Abecma (idecabtagene vicleucel) is the other approved BCMA CAR-T in multiple myeloma and the most direct head-to-head, competing on efficacy, safety, and slot availability at treatment centers.
Off-the-shelf BCMA bispecifics and ADCs
BCMA-targeting bispecific antibodies like J&J's Tecvayli (teclistamab) and Pfizer's Elrexfio (elranatamab), plus GSK's antibody-drug conjugate Blenrep, offer off-the-shelf dosing that sidesteps CAR-T's manufacturing wait and logistics, and are being pushed into earlier lines.
Large oncology and cell-therapy developers
Big pharma and biotech players in blood-cancer immunotherapy, including partner-turned-rival dynamics at Johnson & Johnson and broader CAR-T developers like Gilead's Kite unit and Novartis, shape pricing, trial design, and the competitive standard of care.
What stocks are similar to Legend Biotech Corporation (LEGN)?
Other names that sit close to LEGN: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in Legend Biotech Corporation (LEGN)
There are three common ways to get LEGN exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so LEGN sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where LEGN fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Legend Biotech Corporation (LEGN)
LEGN is effectively a one-product CAR-T story riding CARVYKTI's ramp with J&J, so the payoff and the risk both hinge on that single franchise. Legend has now posted GAAP profits in Q2 and Q3 2026, but the stock sits near its 52-week low because US demand decelerated and rival myeloma therapies are closing in, including Gilead's anito-cel CAR-T, which faces an FDA decision on December 23, 2026.
More on Legend Biotech Corporation (LEGN)
Whether LEGN is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is LEGN a buy or a sell?, and where the stock could go from here in the LEGN stock forecast.
For income investors, whether LEGN pays a dividend and how the payout looks is covered in does LEGN pay a dividend? And to weigh LEGN against a peer, read the full side-by-side comparisons: LEGN vs CAR and LEGN vs BMY.
Wondering how LEGN fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Legend Biotech Corporation
Ask Walnut's AI anything about LEGN and see how it fits what you own.
FAQ
What does Legend Biotech do?
+
Legend Biotech is a cell-therapy company whose flagship product is CARVYKTI, a one-time BCMA-directed CAR-T treatment for relapsed or refractory multiple myeloma. It co-develops and shares profits on CARVYKTI with Johnson & Johnson and runs an earlier-stage pipeline of other cell therapies.
Is LEGN a US-listed stock?
+
Yes. Legend Biotech trades on the Nasdaq under the ticker LEGN as an American Depositary Receipt. The company was founded in China and is legally domiciled outside the US, which adds ADR and geopolitical considerations for investors.
What is CARVYKTI and why does it matter so much?
+
CARVYKTI (cilta-cel) is a personalized CAR-T therapy that reengineers a patient's own T cells to attack BCMA-expressing myeloma cells. It generated roughly $1.9 billion in global net trade sales in 2025 and about $710 million in Q3 2026 alone, and it is essentially the entire commercial story, so its trajectory drives the stock.
How does Legend make money from CARVYKTI?
+
Legend shares CARVYKTI's costs and profits with Johnson & Johnson under a collaboration. As a result, its reported revenue appears largely as collaboration and license income rather than direct product sales, and it captures roughly half of the franchise economics (about $355 million of the Q3 2026 sales).
Is Legend Biotech profitable?
+
It has been for two quarters. Legend reported its first quarterly GAAP profit in Q2 2026, net income of about $33.2 million, then about $51.7 million in Q3 2026, after a full-year 2025 adjusted net loss of about $33 million and a Q1 2026 adjusted net loss of roughly $10.5 million. On a trailing twelve-month basis net income is roughly breakeven, and analysts expect about $0.12 of EPS for 2026 and about $0.54 per share in 2027.
Who competes with CARVYKTI?
+
Its closest rival is Bristol Myers Squibb's Abecma, the other approved BCMA CAR-T. It also faces off-the-shelf BCMA bispecific antibodies like J&J's Tecvayli and Pfizer's Elrexfio, plus GSK's ADC Blenrep, which avoid CAR-T's manufacturing wait. Gilead's anito-cel, another BCMA CAR-T, has an FDA decision date of December 23, 2026.
What are the biggest risks for LEGN?
+
Concentration in a single product and a single partner, a crowded multiple-myeloma market, slowing US growth, CAR-T manufacturing and capacity constraints, serious safety considerations, a short profit record, and ADR-related geopolitical and regulatory exposure are the main risks that can move the stock sharply.
How did Legend Biotech do in its latest quarter?
+
In Q3 2026 (ended September 30, reported November 10) Legend reported total revenue of about $359.5 million, up 32% year over year and in line with consensus, and net income of about $51.7 million, with adjusted EPS well above the $0.01 consensus. CARVYKTI net trade sales rose 36% to about $710 million, but US growth slowed to 19% from 32% the prior quarter, and the shares fell about 18% that day. For Q4 2026, analysts expect about $0.06 per share on about $360 million of revenue.
How has LEGN stock performed in 2026?
+
As of the November 20, 2026 close of $15.42, LEGN was down about 28% year to date and about 44% over the past year, just above its 52-week low of $15.36 (the high was $37.50). The decline came despite rising sales and two profitable quarters, as investors focused on slowing US demand and new competition in multiple myeloma; the stock fell about 20% over the last month and about 28% over three months.
What did the five-year CARVYKTI data show?
+
In September 2026 Legend presented data showing that half of patients with relapsed or refractory multiple myeloma remained alive and progression-free five years after a single CARVYKTI infusion. Its Q3 release also cited five-year CARTITUDE-2 Cohort A data with median progression-free survival of 60.5 months and 69.2% of patients alive at five years. Long-term durability of this kind is central to the case for using a one-time CAR-T earlier in treatment rather than ongoing off-the-shelf therapies.
Who runs Legend Biotech?
+
Ingrid Zhang became Legend Biotech's chief executive officer effective September 15, 2026, according to the company's third-quarter 2026 results release. She took over as the company was reaching quarterly profitability and facing new competition in multiple myeloma.
How can I invest in LEGN through Walnut?
+
You can add LEGN to a thematic basket in Walnut, connect your brokerage, and place orders that bring the basket toward your target weights. Walnut is not an investment adviser, so any decision to buy or sell LEGN is your own.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Legend Biotech Corporation's investor relations page or your broker before making investment decisions.